Drugs / TAK-981
Trials 6 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 01 trial | ||||||
| Phase 0 | NCT04065555 | Oct 2020 → Jun 2022 | head and neck cancer | Presage Biosciences | Completed | No outcome recorded |
| Phase 11 trial | ||||||
| Phase 1 | NCT05976334 | Nov 2023 → Jun 2024 | cancer | Takeda | Terminated | No outcome recorded |
| Phase 1/24 trials | ||||||
| Phase 1/2 | NCT04776018 | Apr 2021 → Aug 2023 | refractory plasma cell neoplasm | Takeda | Terminated | No outcome recorded |
| Phase 1/2 | NCT04381650 | Aug 2020 → Oct 2024 | — | Takeda | Completed | No outcome recorded |
| Phase 1/2 | NCT04074330 | Oct 2019 → Apr 2023 | non-Hodgkin lymphoma | Takeda | Terminated | No outcome recorded |
| Phase 1/2 | NCT03648372 | Oct 2018 → Nov 2023 | lymphoma | Takeda | Terminated | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 8 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | TAK-981 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04381650 ↗ |
| Known as | subasumstat | “TAK-981 (subasumstat), an investigational drug that inhibits SUMOylation by targeting SUMO-activating enzymes, has demonstrated high potential for the treatment of various cancers.” PMID 40373381 ↗ May 20252“In this report, we have explored the activity of the selective small molecule SUMOylation inhibitor subasumstat (TAK-981) in promoting antitumor innate immune responses.” PMID 35226739 ↗ May 2022 |
| Action | Inhibit | “selective small molecule SUMOylation inhibitor subasumstat (TAK-981)” PMID 35226739 ↗ May 2022 |
| Modality | Small molecule | “selective small molecule SUMOylation inhibitor subasumstat (TAK-981)” PMID 35226739 ↗ May 2022 |
| Route | Intravenous | “TAK-981 intravenously administered as 60 minute-infusion” NCT03648372 ↗ |